Protalix BioTherapeutics, Inc.PLXNYSE
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +73.60% | +73.74% | +169.82% | +16.21% | -0.60% |
| Gross Profit Growth | +75.79% | +779.26% | +68.67% | +143.60% | -0.59% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -37.58% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -46.60% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -27.22% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -31.82% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -10.98% |
| Weighted Average Shares Growth | +1.75% | +0.82% | +4.89% | +7.31% | +7.79% |
| Weighted Average Shares Diluted Growth | -3.06% | +11.11% | +4.89% | +10.86% | -0.50% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +11.02% | -220.77% | +0.00% | -190.91% |
| Free Cash Flow Growth | +0.00% | +6.61% | -249.42% | +0.00% | -205.28% |
| Receivables Growth | -75.43% | -44.82% | +24.37% | -6.75% | +557.18% |
| Inventory Growth | -20.31% | +11.54% | -12.71% | +1.99% | +23.58% |
| Asset Growth | -29.70% | -13.05% | -17.74% | -14.26% | +33.63% |
| Book Value per Share Growth | -16.65% | +27.68% | +44.69% | +62.71% | +51.32% |
| Debt Growth | -78.14% | -78.97% | -80.15% | -80.62% | +43.86% |
| R&D Expense Growth | -18.29% | +32.95% | +20.37% | +102.36% | +49.00% |
| SG&A Expenses Growth | -29.29% | -27.61% | -16.44% | -24.68% | +12.87% |